share_log

Reneo Pharmaceuticals (NASDAQ:RPHM) Trading Up 2%

Reneo Pharmaceuticals (NASDAQ:RPHM) Trading Up 2%

Reneo Pharmicals（纳斯达克股票代码：RPHM）交易上涨2％
Defense World ·  2023/01/25 02:41

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM – Get Rating)'s stock price was up 2% during trading on Tuesday . The stock traded as high as $2.64 and last traded at $2.55. Approximately 125,887 shares traded hands during trading, an increase of 180% from the average daily volume of 44,959 shares. The stock had previously closed at $2.50.

Reneo Pharmicals, Inc.（纳斯达克股票代码：RPHM — 获取评级）的股价在周二的交易中上涨了2％。该股交易价格高达2.64美元，最后一次交易价格为2.55美元。交易期间约有125,887股交易，较平均每日交易量44,959股增加了180％。该股此前收于2.50美元。

Reneo Pharmaceuticals Stock Up 2.0 %

Reneo Pharmicals股价上涨2.

The company's 50 day moving average price is $2.30 and its 200 day moving average price is $2.91. The firm has a market capitalization of $62.55 million, a price-to-earnings ratio of -1.28 and a beta of 0.50.

该公司的50天移动平均价格为2.30美元，其200天移动平均线价格为2.91美元。该公司的市值为6,255万美元，市盈率为-1.28，beta值为0.50。

Get
获取
Reneo Pharmaceuticals
Reneo 制药
alerts:
警报：

Reneo Pharmaceuticals (NASDAQ:RPHM – Get Rating) last issued its earnings results on Tuesday, November 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.05. As a group, analysts expect that Reneo Pharmaceuticals, Inc. will post -2.16 earnings per share for the current year.

Reneo Pharmicals（纳斯达克股票代码：RPHM — 获取评级）最后一次发布财报是在11月8日星期二。该公司公布的本季度每股收益（EPS）（0.53美元），比市场普遍预期的（0.58美元）高出0.05美元。作为一个整体，分析师预计，Reneo Pharmicals, Inc.将公布本年度的每股收益为-2.16％。

Institutional Inflows and Outflows

机构流入和流出

Several institutional investors have recently made changes to their positions in RPHM. Renaissance Technologies LLC purchased a new position in shares of Reneo Pharmaceuticals during the second quarter worth $61,000. Dimensional Fund Advisors LP purchased a new position in shares of Reneo Pharmaceuticals during the third quarter worth $62,000. Federated Hermes Inc. increased its holdings in Reneo Pharmaceuticals by 76.5% in the second quarter. Federated Hermes Inc. now owns 30,000 shares of the company's stock valued at $80,000 after buying an additional 13,000 shares in the last quarter. Bank of America Corp DE raised its position in shares of Reneo Pharmaceuticals by 24.0% in the first quarter. Bank of America Corp DE now owns 40,878 shares of the company's stock worth $121,000 after acquiring an additional 7,914 shares during the period. Finally, UBS Group AG boosted its stake in shares of Reneo Pharmaceuticals by 5,012.5% during the 2nd quarter. UBS Group AG now owns 54,550 shares of the company's stock worth $145,000 after acquiring an additional 53,483 shares in the last quarter. Hedge funds and other institutional investors own 75.61% of the company's stock.
几位机构投资者最近改变了他们在RPHM的头寸。Renaissance Technologies LLC在第二季度购买了价值61,000美元的Reneo Pharmicals股票的新Dimensional Fund Advisors LP在第三季度购买了价值62,000美元的Reneo Pharmicals股票的新头寸联邦爱马仕公司在第二季度将其在Reneo Pharmicals的持股量增加了76.5％。联邦爱马仕公司在上个季度又购买了13,000股股票后，现在拥有该公司3万股股票，价值8万美元。美国银行德意志银行在第一季度将其在Reneo Pharmicals的股票头寸上调了24.0％。美国银行德意志银行在此期间又收购了7,914股股票后，现在拥有该公司40,878股股票，价值12.1万美元。最后，瑞银集团股份公司在第二季度将其在Reneo Pharmicals的股份增加了5,012.5％。瑞银集团股份公司在上个季度又收购了53,483股股票后，现在拥有该公司54,550股股票，价值14.5万美元。对冲基金和其他机构投资者拥有该公司75.61％的股票。

About Reneo Pharmaceuticals

关于 Reneo 制药

(Get Rating)

（获取评分）

Reneo Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.

Reneo Pharmicals, Inc是一家处于临床阶段的制药公司，专注于罕见遗传线粒体疾病患者的疗法的开发和商业化。其主要候选产品是 REN001，这是一种强效的选择性过氧化物酶体增殖物激活受体 delta 的激动剂，正在临床开发用于遗传线粒体疾病，包括原发性线粒体肌病和长链脂肪酸氧化障碍。

Further Reading

进一步阅读

  • Get a free copy of the StockNews.com research report on Reneo Pharmaceuticals (RPHM)
  • EVgo Stock is Charged Up to Ride the EV Adoption Wave
  • Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
  • High-Yield, Deep-Value Verizon Puts In A Bottom
  • Can Coty Stock Emerge in 2023 With Upside
  • Should You Bet Against The Nasdaq 100 With This Inverse ETF?
  • 免费获取 StockNews.com 关于 Reneo Pharmicals（RPHM）的研究报告的副本
  • EvGo 股票备受冲击，可以顺应电动汽车的采用浪潮
  • 高通得到了分析师的提振，但现在是买入的时候了吗？
  • 高收益、深层价值的Verizon跌入谷底
  • 科蒂股票能否在 2023 年出现上行空间
  • 你应该用这个反向ETF押注纳斯达克100吗？

Receive News & Ratings for Reneo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reneo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

接收Reneo Pharmicals每日的新闻和收视率 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收Reneo Pharmicals及相关公司最新新闻和分析师评级的简明每日摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发